GC
GSK icon

Grimes & Company’s GSK GSK Stock Holding History

Grimes & Company’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.58M Buy
182,745
+434
+0.2% +$23K 0.21% 84
2026
Q1 		$10.1M Sell
182,311
-3,253
-2% -$176K 0.28% 76
2025
Q4 		$9.1M Sell
185,564
-10,756
-5% -$502K 0.22% 83
2025
Q3 		$8.47M Sell
196,320
-5,132
-3% -$200K 0.21% 87
2025
Q2 		$7.74M Buy
201,452
+45,143
+29% +$1.72M 0.21% 96
2025
Q1 		$6.06M Buy
156,309
+16,434
+12% +$602K 0.19% 99
2024
Q4 		$4.73M Buy
+139,875
New +$5.04M 0.14% 103
2016
Q4 		– Sell
-4,522
Closed -$244K – 207
2016
Q3 		$244K Buy
4,522
+228
+5% +$12.5K 0.03% 172
2016
Q2 		$232K Buy
4,294
+188
+5% +$9.9K 0.03% 181
2016
Q1 		$209K Sell
4,106
-1,212
-23% -$60.4K 0.03% 182
2015
Q4 		$268K Buy
5,318
+1,056
+25% +$53.8K 0.04% 163
2015
Q3 		$205K Buy
+4,262
New +$222K 0.03% 176
2015
Q2 		– Sell
-3,664
Closed -$212K – 195
2015
Q1 		$212K Buy
+3,664
New +$210K 0.05% 147
2014
Q3 		– Sell
-3,098
Closed -$207K – 170
2014
Q2 		$207K Buy
3,098
+92
+3% +$6.23K 0.05% 148
2014
Q1 		$201K Buy
+3,006
New +$203K 0.06% 138

Other funds holding GSK

MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
FVWA
Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Grimes & Company's GSK Position: Q2 2026 in Review

Grimes & Company increased its GSK (GSK) stake by 0.24% in Q2 2026, buying an estimated $23K and bringing the position to 182,745 shares worth $9.58M. The position accounts for 0.21% of the portfolio, ranked #84.

Grimes & Company first reported a position in GSK in Q1 2014 and has held it in 15 quarters since. The position peaked at $10.1M in Q1 2026. 418 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Grimes & Company held 182,745 shares of GSK worth $9.58M as of Q2 2026.
  • Grimes & Company bought 434 GSK shares in Q2 2026, an estimated $23K.
  • GSK made up 0.21% of Grimes & Company's portfolio in Q2 2026, its #84 holding.
  • Grimes & Company first reported a position in GSK in Q1 2014 and has held it in 15 quarters since.
  • Grimes & Company's GSK position peaked at $10.1M in Q1 2026.
  • 418 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.